BT 1053
Alternative Names: BT-1053Latest Information Update: 25 Aug 2023
At a glance
- Originator ScinnoHub Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma
Most Recent Events
- 14 Jul 2023 Phase-I clinical trials in Lymphoma in China (PO) (ScinnoHub Pharmaceutical pipeline, July 2023)